Efficacy of biologics in atopic dermatitis

References

• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European academy of allergology and clinical immunology/American academy of allergy, asthma and immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2006;118(1):152–169.
   PubMed Web of Science ®Google Scholar
• Nagaraja KAJ, Dhar S, Singh S. Frequency and significance of minor clinical features in various age-related subgroups of atopic dermatitis in children. Pediatr Dermatol. 1996;13(1):10–13.
   PubMed Web of Science ®Google Scholar
• Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526–1532.e1527.
   PubMed Web of Science ®Google Scholar
• Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595–605.
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289.
   PubMed Web of Science ®Google Scholar
• Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124(6):1251–1258.e1223.
   PubMed Web of Science ®Google Scholar
• Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 national survey of children’s health. J Invest Dermatol. 2011;131(1):67–73.
   PubMed Web of Science ®Google Scholar
• Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340–357.
   PubMed Web of Science ®Google Scholar
• Williams HC, Pembroke AC, Forsdyke H, et al. London-born black Caribbean children are at increased risk of atopic dermatitis. J Am Acad Dermatol. 1995;32(2):212–217.
   PubMed Web of Science ®Google Scholar
• Janumpally SR, Feldman SR, Gupta AK, et al. In the United States, blacks and Asian/Pacific Islanders are more likely than whites to seek medical care for atopic dermatitis. Arch Dermatol. 2002;138(5):634–637.
   PubMedGoogle Scholar
• Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part I: clinical and pathologic concepts. J Allergy Clin Immunol. 2011;127(5):1110–1118.
   PubMed Web of Science ®Google Scholar
• Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354.
   PubMed Web of Science ®Google Scholar
• Silvestre Salvador JF, Romero-Perez D, Encabo-Duran B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78–88.
   PubMed Web of Science ®Google Scholar
• Megna M, Patruno C, Balato A, et al. An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease. Arch Dermatol Res. 2017;309(6):443–452.
   PubMed Web of Science ®Google Scholar
• Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17–27.
   PubMed Web of Science ®Google Scholar
• Belgrave DC, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Ann Allergy Asthma Immunol. 2018;120(1):34–41.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734.
   PubMed Web of Science ®Google Scholar
• Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603–613.
   PubMed Web of Science ®Google Scholar
• Noda S, Suarez-Farinas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–1264.
   PubMed Web of Science ®Google Scholar
• TC SR C, Pavel AB, Glickman J, et al. Variable TH2/TH17-skewing places Chinese atopic dermatitis and psoriasis on an inflammatory spectrum. J Invest Dermatol. 2018;138(5, Supplement):S10.
   Google Scholar
• Sanyal RD, Pavel AB, Glickman J, et al. Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. Ann Allergy Asthma Immunol. 2019;122(1):99–110.e116.
   PubMed Web of Science ®Google Scholar
• Chan TC, Sanyal RD, Pavel AB, et al. Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features. J Allergy Clin Immunol. 2018;142(3):1013–1017.
   PubMed Web of Science ®Google Scholar
• Zhou L, Leonard A, Pavel AB, et al. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2019;144(1):144–156.
   PubMed Web of Science ®Google Scholar
• Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–1651.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Israel A, Zhang N, et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol. 2018;141(6):2094–2106.
   PubMed Web of Science ®Google Scholar
• Suarez-Farinas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361–370.
   PubMed Web of Science ®Google Scholar
• Brunner PM, He H, Pavel AB, et al. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. J Am Acad Dermatol. 2019;81(2):510–519.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Israel A, Leonard A, et al. Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. Ann Allergy Asthma Immunol. 2019;122(3):318–330.e313.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, He H, Canter T, et al. Evolution of pathologic T-cell subsets in atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2020;145(1):215–228.
   Web of Science ®Google Scholar
• He H, Li R, Choi S, et al. Increased cardiovascular and atherosclerosis markers in blood of older atopic dermatitis patients. Ann Allergy Asthma Immunol. 2020;124(1):70–78.
   Web of Science ®Google Scholar
• Czarnowicki T, Malajian D, Shemer A, et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. J Allergy Clin Immunol. 2015;136(1):208–211.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18–25.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? recommendations from an expert panel of the international eczema council. J Am Acad Dermatol. 2017;77(4):623–633.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349.
   PubMed Web of Science ®Google Scholar
• He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–192.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaci D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2019. doi: 10.1016/j.jaci.2019.11.025.
   Google Scholar
• Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA dermatology. 2020;155(12):1371–1379.
   Web of Science ®Google Scholar
• Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921.e919.
   PubMed Web of Science ®Google Scholar
• Pavel AB, Song T, Kim HJ, et al. Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis. J Allergy Clin Immunol. 2019;144:1011–1024.
   Web of Science ®Google Scholar
• Bissonnette R, Maari C, Forman S, et al. The oral janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019;181(4):733–742.
   PubMed Web of Science ®Google Scholar
• Thaci D, Simpson EL, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303.
   PubMed Web of Science ®Google Scholar
• Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol. 2001;117(4):977–983.
   PubMed Web of Science ®Google Scholar
• Zheng T, Oh MH, Oh SY, et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129(3):742–751.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Kantor R. The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):327–334.
   PubMed Web of Science ®Google Scholar
• Kim BE, Leung DY, Boguniewicz M, et al. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332–337.
   PubMed Web of Science ®Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7–r12.
   PubMed Web of Science ®Google Scholar
• Oh MH, Oh SY, Yu J, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol. 2011;186(12):7232–7242.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Hamilton J, Hamon S, Simpson E, et al. 372 The effect of dupilumab on biomarkers in a randomized phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis. J Invest Dermatol. 2016;136(9):S224.
   Web of Science ®Google Scholar
• Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293–1300.
   PubMed Web of Science ®Google Scholar
• Frampton JE, Blair HA. Dupilumab: a review in moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2018;19(4):617–624.
   PubMed Web of Science ®Google Scholar
• de Bruin-weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178(5):1083–1101.
   PubMed Web of Science ®Google Scholar
• Wang -H-H, Li Y-C, Huang Y-C. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2016;138(6):1719.
   PubMed Web of Science ®Google Scholar
• Han Y, Chen Y, Liu X, et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2017;140(3):888–891.e886.
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Esposito M, Ferrucci S, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatol Treat. 2019. p. 1–7. doi: 10.1080/09546634.2019.1682503.
   Web of Science ®Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, de Bruin-weller MS, Paller AS, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. J Eur Acad Dermatol Venereol. 2019;33(7):1224–1231.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Ariens L, Thurau S, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):1778–1780.e1771.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Scalvenzi M, Fabbrocini G, et al. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series. Dermatol Ther. 2019;32(6):e13142.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Scalvenzi M, et al. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis. Dermatitis. 2020;31:81–84.
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125–137.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172.
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7(10):1043–1058.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–141.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863–871.e811.
   PubMed Web of Science ®Google Scholar
• Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330–1339.
   PubMed Web of Science ®Google Scholar
• Popovic B, Breed J, Rees DG, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2. J Mol Biol. 2017;429(2):208–219.
   PubMed Web of Science ®Google Scholar
• Izuhara K, Arima K, Ohta S, et al. Periostin in allergic inflammation. Allergol Int. 2014;63(2):143–151.
   Web of Science ®Google Scholar
• Ranade K, Pham T-H, Damera G, et al. Dipeptidyl Peptidase-4 (DPP-4) Is a Novel Predictive Biomarker for the Investigational Anti-IL-13 Targeted Therapy Tralokinumab. B101 PHENOTYPING OF ASTHMA IN THE ERA OF BIOMARKERS AND OMICS. American Thoracic Society International Conference Abstracts: American Thoracic Society; 2016. p. A4332-A.
   Google Scholar
• Poole A, Urbanek C, Eng C, et al. Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease. J Allergy Clin Immunol. 2014;133(3):670–678.e612.
   PubMed Web of Science ®Google Scholar
• Parulekar AD, Atik MA, Hanania NA. Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med. 2014;20(1):60–65.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E Lebrikizumab, a high affinity IL-13 inhibitor, improves clinical manifestations in moderate-to-severe atopic dermatitis: primary results from a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study, Fall Clinical Dermatology Conference, Las Vegas, NV. October 2019. 3 41
   Google Scholar
• https://www.dermira.com/pipeline/lebrikizumab/. cited 2019 Oct.
   Google Scholar
• Leiferman KM. Eosinophils in atopic dermatitis. J Allergy Clin Immunol. 1994;94(6):1310–1317.
   PubMed Web of Science ®Google Scholar
• Oldhoff J, Darsow U, Werfel T, et al. Anti‐IL‐5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60(5):693–696.
   PubMed Web of Science ®Google Scholar
• Kang EG, Narayana PK, Pouliquen IJ, et al. Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis. Allergy. 2019. doi: 10.1111/all.14050.
   Google Scholar
• Szegedi K, Kremer AE, Kezic S, et al. Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol. 2012;21(6):431–436.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417.
   PubMed Web of Science ®Google Scholar
• Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752–760.
   PubMed Web of Science ®Google Scholar
• Kato A, Fujii E, Watanabe T, et al. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. J Dermatol Sci. 2014;74(3):229–235.
   PubMed Web of Science ®Google Scholar
• Bando T, Morikawa Y, Komori T, et al. Complete overlap of interleukin-31 receptor A and oncostatin M receptor β in the adult dorsal root ganglia with distinct developmental expression patterns. Neuroscience. 2006;142(4):1263–1271.
   PubMed Web of Science ®Google Scholar
• Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron–expressed IL-31 receptor mediates T helper cell–dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133(2):448–460. e447.
   PubMed Web of Science ®Google Scholar
• Grimstad O, Sawanobori Y, Vestergaard C, et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol. 2009;18(1):35–43.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173–182.
   Web of Science ®Google Scholar
• Nemolizumab achieves primary endpoint in phase 3 clinical study (comparative study) in Japan for the treatment of atopic dermatitis. Maruho co., ltd. April18, 2019 Cited 2019 Oct. Available from: https://www.maruho.co.jp/english/release/nek5p40000004lm8-att/20190418_pr_eng.pdf
   Google Scholar
• Nakajima S, Igyártó BZ, Honda T, et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. J Allergy Clin Immunol. 2012;129(4):1048–1055.e1046.
   PubMed Web of Science ®Google Scholar
• Liu YJ. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol. 2007;120(2): 238–244. quiz 245-236.
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673–680.
   PubMed Web of Science ®Google Scholar
• Tidwell WJ, Fowler JF Jr. T-cell inhibitors for atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S67–s70.
   PubMed Web of Science ®Google Scholar
• Godfrey WR, Fagnoni FF, Harara MA, et al. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med. 1994;180(2):757–762.
   PubMed Web of Science ®Google Scholar
• Wang YH, Ito T, Wang YH, et al. Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity. 2006;24(6):827–838.
   PubMed Web of Science ®Google Scholar
• Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med. 2005;202(4):541–549.
   PubMed Web of Science ®Google Scholar
• Li M, Messaddeq N, Teletin M, et al. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci U S A. 2005;102(41):14795–14800.
   PubMed Web of Science ®Google Scholar
• He R, Oyoshi MK, Garibyan L, et al. TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. Proc Natl Acad Sci U S A. 2008;105(33):11875–11880.
   PubMed Web of Science ®Google Scholar
• Gao P-S, Rafaels NM, Mu D, et al. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. J Allergy Clin Immunol. 2010;125(6):1403–1407. e1404.
   PubMed Web of Science ®Google Scholar
• Savinko T, Matikainen S, Saarialho-Kere U, et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol. 2012;132(5):1392–1400.
   PubMed Web of Science ®Google Scholar
• Miller AM. Role of IL-33 in inflammation and disease. J Inflam. 2011;8(1):22.
   Google Scholar
• Murakami-Satsutani N, Ito T, Nakanishi T, et al. IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand. Allergol Int. 2014;63(3):443–455.
   Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–490.
   PubMed Web of Science ®Google Scholar
• Seltmann J, Roesner LM, von Hesler FW, et al. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol. 2015;135(6):1659–1661.e1654.
   PubMed Web of Science ®Google Scholar
• Peng G, Mu Z, Cui L, et al. Anti-IL-33 antibody has a therapeutic effect in an atopic dermatitis murine model induced by 2, 4-dinitrochlorobenzene. Inflammation. 2018;41(1):154–163.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(2):482–493.e487.
   PubMed Web of Science ®Google Scholar
• Glenmark pharmaceuticals announces presentation of new subtype analysis of GBR 830, an investigational, anti-OX40 monoclonal antibody, at the American academy of dermatology annual meeting. Glenmark Pharmaceuticals. March 1, 2019 Cited 2019 Oct. Available from: https://www.prnewswire.com/news-releases/glenmark-pharmaceuticals-announces-presentation-of-new-subtype-analysis-of-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-the-american-academy-of-dermatology-annual-meeting-300804542.html
   Google Scholar
• Nakagawa H P0252, EADV 2018. 2018.
   Google Scholar
• Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4):1013–1021.
   PubMed Web of Science ®Google Scholar
• Chen Y-L, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019;11(515):eaax2945.
   PubMed Web of Science ®Google Scholar
• Boniface K, Diveu C, Morel F, et al. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol. 2007;178(7):4615.
   PubMed Web of Science ®Google Scholar
• Ishihara K, Hirano T. Molecular basis of the cell specificity of cytokine action. Biochim Biophys Acta-Mol Cell Res. 2002;1592(3):281–296.
   Web of Science ®Google Scholar
• Gazel A, Rosdy M, Bertino B, et al. A characteristic subset of psoriasis-associated genes is induced by oncostatin-M in reconstituted epidermis. J Invest Dermatol. 2006;126(12):2647–2657.
   PubMed Web of Science ®Google Scholar
• Raap U, Gehring M, Kleiner S, et al. Human basophils are a source of - and are differentially activated by - IL-31. Clin Exp Allergy. 2017;47(4):499–508.
   PubMed Web of Science ®Google Scholar
• Kiniksa announces interim data from KPL-716 repeated-single-dose phase 1b clinical trial. kiniksa pharmaceuticals, ltd. August 12, 2019. Cited 2019 Oct Available from: https://www.globenewswire.com/news-release/2019/08/12/1900693/0/en/Kiniksa-Announces-Interim-Data-from-KPL-716-Repeated-Single-Dose-Phase-1b-Clinical-Trial.html
   Google Scholar
• Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123(6):1244–1252.e1242.
   PubMed Web of Science ®Google Scholar
• Boniface K, Bernard FX, Garcia M, et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005;174(6):3695–3702.
   PubMed Web of Science ®Google Scholar
• Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol. 2011;165(3):492–498.
   PubMed Web of Science ®Google Scholar
• Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;178(4):2229.
   PubMed Web of Science ®Google Scholar
• Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2:3.
   Google Scholar
• Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573–3585.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Ungar B, Malik K, et al. Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis. J Allergy Clin Immunol. 2017;140(4):1032–1042.e1013.
   PubMed Web of Science ®Google Scholar
• Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol. 2014;133(6):1626–1634.
   PubMed Web of Science ®Google Scholar
• Tintle S, Shemer A, Suarez-Farinas M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011;128(3):583–593.e581-584.
   Web of Science ®Google Scholar
• Brunner PM, Khattri S, Garcet S, et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2016;138(1):169–178.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(5):872–881.e876.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Pavel AB, Khattri S, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol. 2019;143(1):142–154.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Krueger JG. IL-17C: a unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis. J Invest Dermatol. 2018;138(7):1467–1469.
   PubMed Web of Science ®Google Scholar
• Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. Cytokine. 2013;64(2):477–485.
   PubMed Web of Science ®Google Scholar
• Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12(12):1159.
   PubMed Web of Science ®Google Scholar
• Chang SH, Reynolds JM, Pappu BP, et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35(4):611–621.
   PubMed Web of Science ®Google Scholar
• Song X, Zhu S, Shi P, et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol. 2011;12(12):1151.
   PubMed Web of Science ®Google Scholar
• Vandeghinste N, Klattig J, Jagerschmidt C, et al. Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis. J Invest Dermatol. 2018;138(7):1555–1563.
   PubMed Web of Science ®Google Scholar
• Ewald DA, Noda S, Oliva M, et al. Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. J Allergy Clin Immunol. 2017;139(2):562–571.
   PubMed Web of Science ®Google Scholar
• Suarez-Farinas M, Ungar B, Correa da Rosa J. Correa da Rosa J, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol. 2015;135(5):1218–1227.
   PubMed Web of Science ®Google Scholar
• Thaci D. AAD 2018 late-breaking research: clinical trials. Feb 16–20, 2018.
   Google Scholar
• https://www.morphosys.com/media-investors/media-center/morphosys-ag-mor106-clinical-development-in-atopic-dermatitis-stopped. Cited 2019 Oct 29.
   Google Scholar
• Abramovits W, Rivas Bejarano JJ, Valdecantos WC. Role of interleukin 1 in atopic dermatitis. Dermatol Clin. 2013;31(3):437–444.
   PubMed Web of Science ®Google Scholar
• Netea MG, Nold-Petry CA, Nold MF, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. Blood. 2009;113(10):2324–2335.
   PubMed Web of Science ®Google Scholar
• Granowitz EV, Clark BD, Vannier E, et al. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood. 1992;79(9):2356–2363.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Ikejima T, Warner S, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol. 1987;139(6):1902–1910.
   PubMed Web of Science ®Google Scholar
• Kupper TS, Ballard DW, Chua A, et al. Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1. J Exp Med. 1986;164(6):2095–2100.
   PubMed Web of Science ®Google Scholar
• Sauder DN. Biologic properties of epidermal cell thymocyte-activating factor (ETAF). J Invest Dermatol. 1985;85(1):S176–S179.
   Web of Science ®Google Scholar
• Kumar S, Millis A, Baglioni C. Expression of interleukin 1-inducible genes and production of interleukin 1 by aging human fibroblasts. Proc Nat Acad Sci. 1992;89(10):4683–4687.
   PubMed Web of Science ®Google Scholar
• Sauder DN, Dinarello CA, Morhenn VB. Langerhans cell production of interleukin-1. J Invest Dermatol. 1984;82(6):605–607.
   PubMed Web of Science ®Google Scholar
• Yano S, Banno T, Walsh R, et al. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin‐1. J Cell Physiol. 2008;214(1):1–13.
   PubMed Web of Science ®Google Scholar
• Mee JB, Johnson CM, Morar N, et al. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol. 2007;171(1):32–42.
   PubMed Web of Science ®Google Scholar
• Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) Pathway. Sci Signal. 2010;3(105):cm1.
   PubMed Web of Science ®Google Scholar
• Gresnigt MS, van de Veerdonk FL Biology of IL-36 cytokines and their role in disease. Paper presented at: seminars in immunology. 2013.
   Google Scholar
• Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89.
   PubMed Web of Science ®Google Scholar
• Vigne S, Palmer G, Lamacchia C, et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011;118(22):5813–5823.
   PubMed Web of Science ®Google Scholar
• Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89–102.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB. EADV 2019, D3T01.1F. October 2019.
   Google Scholar
• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66–73.
   PubMed Web of Science ®Google Scholar
• Suárez-Fariñas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277–1287.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648–651.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4s):S65–s76.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
   PubMed Web of Science ®Google Scholar
• Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017;26(1):28–35.
   PubMed Web of Science ®Google Scholar
• Saeki H, Kabashima K, Tokura Y, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol. 2017;177(2):419–427.
   PubMed Web of Science ®Google Scholar
• McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79(8):893–900.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277–286. e210.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol. 2019;181(3):604–606.
   PubMed Web of Science ®Google Scholar
• Secukinumab for treatment of atopic dermatitis. June 12, 2019 Cited 2019 Oct. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02594098
   Google Scholar
• Hanifin JM. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Suppl). 1980;92:44–47.
   Google Scholar
• Leung DYM. Role of IgE in atopic dermatitis. Curr Opin Immunol. 1993;5(6):956–962.
   PubMed Web of Science ®Google Scholar
• Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol. 2011;41(3):298–310.
   PubMed Web of Science ®Google Scholar
• Novak N, Bieber T, Kraft S. Immunoglobulin E-bearing antigen-presenting cells in atopic dermatitis. Curr Allergy Asthma Rep. 2004;4(4):263–269.
   PubMed Web of Science ®Google Scholar
• Schafer T, Heinrich J, Wjst M, et al. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol. 1999;104(6):1280–1284.
   PubMed Web of Science ®Google Scholar
• Laske N, Bunikowski R, Niggemann B. Extraordinarily high serum IgE levels and consequences for atopic phenotypes. Ann Allergy Asthma Immunol. 2003;91(2):202–204.
   PubMed Web of Science ®Google Scholar
• Laske N, Niggemann B. Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol. 2004;15(1):86–88.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. Ann Allergy Asthma Immunol. 2020;124(1):28-35.
   Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. What’s new in atopic dermatitis. Dermatol Clin. 2019;37(2):205–213.
   PubMed Web of Science ®Google Scholar
• Moyle M, Cevikbas F, Harden JL, et al. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756–768.
   PubMed Web of Science ®Google Scholar
• Wen HC, Czarnowicki T, Noda S, et al. Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures. J Allergy Clin Immunol. 2018;142(1):324–328.e311.
   PubMed Web of Science ®Google Scholar
• Oliva M, Renert-Yuval Y, Guttman-Yassky E. The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases. Curr Opin Allergy Clin Immunol. 2016;16(5):469–476.
   PubMed Web of Science ®Google Scholar
• Esaki H, Ewald DA, Ungar B, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol. 2015;135(1):153–163.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Suarez-Farinas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7(1):8707.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Diaz A, Pavel AB, et al. Use of tape strips to detect immune and barrier abnormalities in the skin of children with early-onset atopic dermatitis. JAMA Dermatol. 2019;155(12):1358-1370.
   Web of Science ®Google Scholar